Cancer Family
Thymus Neoplasm
CI-CAN-00000366Explore in graph →
Non-malignant104 active trials1 approved drugs1 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000366Explore in graph →
Clinical trials
283 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02628405 | R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma | unknown | Phase 1 / Phase 2 | 30 | Academic and Community Cancer Research UnitedOTHER | 1 | Jul 1, 2024 | clinicaltrials |
| NCT03921671 | Ramucirumab and Carbo-Paclitaxel for Untreated Thymic Carcinoma / B3 Thymoma With Carcinoma (RELEVENT)(RELEVENT) | unknown | Phase 2 | 60 | Claudia ProtoOTHER | 1 | May 29, 2024 |
| clinicaltrials |
| NCT06412068 | A Prospective Study: Sintilimab and R-CHOP in PMBCL Treatment | unknown | Phase 2 | 32 | Sun Yat-sen UniversityOTHER | 0 | May 14, 2024 | clinicaltrials |
| NCT04667793 | Clinical Study of Neoadjuvant PD-1 Antibody (Toripalimab) Plus Chemotherapy for Locally Advanced Thymic Epithelial Tumor | unknown | Phase 2 | 15 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Apr 4, 2023 | clinicaltrials |
| NCT05407649 | Abscopal Effect of Radiotherapy in Combination With rhGM-CSF for Advanced Thymic Epithelial Tumours | unknown | Phase 2 | 60 | Shanghai Cancer Hospital, ChinaOTHER | 1 | Jun 7, 2022 | clinicaltrials |
| NCT03663764 | Hypofractionated Chemoradiotherapy and Thymosin α1 in Unresectable or Recurrent Thymic Epithelial Tumor | unknown | Phase 2 | 57 | Sun Yat-sen UniversityOTHER | 1 | Dec 10, 2021 | clinicaltrials |
| NCT03449173 | Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines (Style Trial)(Style) | unknown | Phase 2 | 56 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Jun 9, 2021 | clinicaltrials |
| NCT04705129 | Zanubrutinib Combined With Tislelizumab in the Treatment of r/r PMBCL and EBV+ DLBCL | unknown | Phase 2 | 40 | Ruijin HospitalOTHER | 1 | Mar 30, 2021 | clinicaltrials |
| NCT03858582 | neoadjuvant_thymic Epithelial Tumor | unknown | Phase 2 | 40 | Samsung Medical CenterOTHER | 1 | Mar 22, 2021 | clinicaltrials |
| NCT04600947 | Study of LP002 for the Treatment of Patients With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma | unknown | Phase 2 | 69 | Taizhou HoudeAoke Biomedical Co., Ltd.INDUSTRY | 1 | Oct 23, 2020 | clinicaltrials |
| NCT04517539 | Abscopal Effect of SBRT in Combination With rhGM-CSF and INF-α 2b for Metastatic Thymic Epithelial Tumors | unknown | Phase 2 | 65 | Shanghai Cancer Hospital, ChinaOTHER | 1 | Aug 18, 2020 | clinicaltrials |
| NCT02364076 | Pembrolizumab and Epacadostat in Patients With Thymic Carcinoma | unknown | Phase 2 | 45 | Georgetown UniversityOTHER | 1 | Dec 13, 2019 | clinicaltrials |
| NCT02747732 | Study of Ibrutinib in Combination With Bendamustine and Rituximab for Patients With Relapsed/Refractory Aggressive BCL | unknown | Phase 2 | 72 | Meirav Kedmi MDOTHER_GOV | 1 | Apr 23, 2019 | clinicaltrials |
| NCT03346642 | Two Stage Study of Combination of Chemotherapy, SHR-1210 and/or Decitabine for Relapsed/Refractory PMBCLs | unknown | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Dec 3, 2018 | clinicaltrials |
| NCT03466827 | Selinexor in Patients With Advanced Thymoma and Thymic Carcinoma(TET-SEL) | unknown | Phase 2 | 25 | Morten Mau-SoerensenOTHER | 2 | Mar 15, 2018 | clinicaltrials |
| NCT03219554 | A Phase II Study of Palbociclib for Recurrent or Refractory Advanced Thymic Epithelial Tumor | unknown | Phase 2 | 33 | Samsung Medical CenterOTHER | 1 | Aug 2, 2017 | clinicaltrials |
Data updated 22 days agoSource updated Jul 1, 2024source: clinicaltrials